Sugi Predict

Sugi Predict / Targets / QPCT

QPCT

Glutaminyl-peptide cyclotransferase · Q16769 · QPCT on Sugi Atlas →

36,202 patent compounds predicted against QPCT, 19,230 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL76673 SCHEMBL76673 1.00 20/20
SCHEMBL78461 SCHEMBL78461 1.00 20/20
SCHEMBL466452 SCHEMBL466452 1.00 20/20
SCHEMBL466492 SCHEMBL466492 0.86 20/20
SCHEMBL466458 SCHEMBL466458 0.85 20/20
SCHEMBL466499 SCHEMBL466499 0.85 20/20
SCHEMBL466507 SCHEMBL466507 0.85 20/20
SCHEMBL466448 SCHEMBL466448 0.85 20/20
SCHEMBL466465 SCHEMBL466465 0.85 20/20
SCHEMBL466518 SCHEMBL466518 0.85 20/20
SCHEMBL466447 SCHEMBL466447 0.84 20/20
SCHEMBL466463 SCHEMBL466463 0.84 20/20
SCHEMBL466498 SCHEMBL466498 0.84 20/20
SCHEMBL466478 SCHEMBL466478 0.84 20/20
SCHEMBL466449 SCHEMBL466449 0.83 20/20
SCHEMBL466468 SCHEMBL466468 0.83 20/20
SCHEMBL466487 SCHEMBL466487 0.83 20/20
SCHEMBL466464 SCHEMBL466464 0.83 20/20
SCHEMBL466474 SCHEMBL466474 0.83 20/20
SCHEMBL466547 SCHEMBL466547 0.82 20/20

Clinical trials — most relevant to QPCT by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Study of Arginine Free IED in Critically Ill Patients. PHASE4COMPLETED
The RE-ENERGIZE Study: RandomizEd Trial of ENtERal Glutamine to minimIZE Thermal Injury PHASE3UNKNOWN
A Trial of CM-AT in Children With Autism With All Levels of FCT (The Blum Study) PHASE3COMPLETED
V-IMMUNE: A Novel Immunoglobulin Therapy for Immunodeficiency PHASE3RECRUITING
NEO100 and High-Grade Meningioma PHASE2RECRUITING
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy PHASE2ACTIVE_NOT_RECRUITING
Wheat Flour Treatment With Microbial Transglutaminase and Lysine Ethyl Ester: New Frontiers in Celiac Disease Treatment. PHASE2UNKNOWN
Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients PHASE2COMPLETED
A Study to Assess CH1504 in Patients With Active Rheumatoid Arthritis PHASE2COMPLETED
Validity Study of Glutamine to Improve Cardiac Function in Cardiac Surgery PHASE2COMPLETED
Therapeutic Efficacy of L-Ornithine L-Aspartate Infusion in Patients With Acute Liver Failure PHASE2UNKNOWN
In Vivo Assessment of Cellular Metabolism in Humans PHASE1COMPLETED
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers PHASE1COMPLETED
The Effects of a Glutathione Precursor (FT061452),on Serum and Intracellular Glutathione Levels PHASE1COMPLETED
Tolerability of Enteral NAC in Infants PHASE1NOT_YET_RECRUITING
Glutamine and Traumatic Brain Injury EARLY_PHASE1UNKNOWN
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine EARLY_PHASE1COMPLETED
Metrology to Enable Rapid and Accurate Clinical Measurements in Acute Management of Sepsis nanUNKNOWN
Effect of Glutamine Supplemented Nutrition Support on Protein and Glutamine Metabolism in Burns nanWITHDRAWN
Transcriptomic Profile of Patients Treated With Different Modalities of Spinal Cord Stimulation nanUNKNOWN
Glutamate Supplementation in Young Men nanCOMPLETED
Use of Blood Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma (HCC) nanUNKNOWN
Proline Metabolism in Severely Burned Patients: Effect of Modulated Parenteral Feeding nanWITHDRAWN
Effect of Nutritional Supplementation and Pulmonary Rehabilitation on the Clinical Status of HF and COPD nanUNKNOWN
Acute Asthma Responsiveness and B2 Adrenergic Receptors Polymorphisms nanCOMPLETED
Discovery of Soluble Biomarkers for Pancreatic Cancer Using Innovative All-Patient Inclusive Methodology nanRECRUITING
Establishing Radiolabelled PSMA as a Target for Glioma Treatment nanNOT_YET_RECRUITING
Analysis by Clinical Mass Spectrometry of Bloodstains nanCOMPLETED
Investigations of the Pathophysiology of Gilles de la Tourette Syndrome. Part 1: Simultaneous PET and 3T MRI nanCOMPLETED
Cognitive Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a QPCT binder may also engage these)

ProteinNameSimilarity
A7ISW2 — 1.000 A7ISW2 →
A7ISW1 — 1.000 A7ISW1 →
Q28120 — 1.000 Q28120 →
Q9CYK2 — 1.000 Q9CYK2 →
Q9YIB5 — 0.998 Q9YIB5 →
Q90YA8 — 0.998 Q90YA8 →
B7QK46 — 0.989 B7QK46 →
Q86PD7 — 0.987 Q86PD7 →
Q9VRQ9 — 0.984 Q9VRQ9 →
P43599 — 0.982 P43599 →
Q7M758 — 0.980 Q7M758 →
Q28193 — 0.978 Q28193 →
P23377 — 0.978 P23377 →
ERMP1 Endoplasmic reticulum metallopeptidase 1 0.978 landscape →
Q9GLD3 — 0.977 Q9GLD3 →
Q9WTZ2 — 0.976 Q9WTZ2 →
O54697 — 0.976 O54697 →
Q6UPR8 — 0.976 Q6UPR8 →
FURIN Furin 0.976 landscape →
P29119 — 0.975 P29119 →
Q07891 — 0.975 Q07891 →
P15087 — 0.975 P15087 →
Q3UVK0 — 0.974 Q3UVK0 →
Q63415 — 0.974 Q63415 →
Q60HF6 — 0.974 Q60HF6 →
Q58D55 — 0.974 Q58D55 →
P23188 — 0.974 P23188 →
Q5R7P4 — 0.974 Q5R7P4 →
P42787 — 0.974 P42787 →
Q96SM3 — 0.974 Q96SM3 →